Patent application number | Description | Published |
20130316316 | DYNAMIC EXERCISE CONTENT - Techniques for dynamic exercise content are described. In implementations, exercise content is provided that includes a variety of different selectable exercise segments that can be individually selected and played back to generate an exercise routine. For example, particular exercise segments can be selected based on user-specified exercise goals, the physical abilities of a particular user, based on various types of feedback, and so on. To assist in the selection of particular exercise segments, exercise segments can be individually tagged with descriptive information, such as using metadata tags. Embodiments can also provide a variety of different types of performance-related feedback to a user during an exercise routine. | 11-28-2013 |
20140244008 | USING A TRUE REPRESENTATION OF EFFORT FOR FITNESS - The subject disclosure is directed towards determining and using effort such as in a fitness/exercise/gaming environment in a way that is substantially independent of a person's height, weight, age, and gender (HWAG) properties. Effort data is recorded that represents a person's effort exerted with respect to performing at least one physical activity, in which effort data is substantially independent of weight, and possibly other HWAG properties. In one aspect, effort duration is used to allow different people to compete against others and/or against established targets/goals substantially equally, independent of a person's HWAG properties. | 08-28-2014 |
20140331242 | MANAGEMENT OF USER MEDIA IMPRESSIONS - Systems, methods, and computer-readable storage media are described herein for aggregating viewing data for one or more types of media content. Image data depicting a viewing area of a display device are received. A type of media content being displayed on the display device when the images are captured is identified. Based on the image data, a number of persons may be determined, as well as characteristics about the persons, responses of the persons toward the media content, and levels of engagement of the persons in the media content, or a portion thereof. Each determined item of information may comprise a viewing record for the media content. The viewing records for the media content may then be aggregated to create viewing data for the content, and the viewing data may be distributed to a content provider. | 11-06-2014 |
Patent application number | Description | Published |
20110200982 | GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., | 08-18-2011 |
20130022996 | GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., | 01-24-2013 |
20130024957 | GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., | 01-24-2013 |
20130042330 | HUMANIZED M-CSF MICE - Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc. | 02-14-2013 |
20140090095 | Genetically Modified Mice and Engraftment - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., | 03-27-2014 |
20140134662 | GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF - Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods. | 05-15-2014 |
20150047061 | Humanized M-CSF Mice - Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc. | 02-12-2015 |
20150208622 | GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF - The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use. | 07-30-2015 |
20150327524 | GENETICALLY MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO - Genetically modified non-human animals expressing human EPO from the animal genome are provided. Also provided are methods for making non-human animals expressing human EPO from the non-human animal genome, and methods for using non-human animals expressing human EPO from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human erythropoiesis and erythrocyte function; in modeling human pathogen infection of erythrocytes; in in vivo screens for agents that modulate erythropoiesis and/or erythrocyte function, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to erythrocytes or erythrocyte progenitors; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on erythrocytes or erythrocyte progenitors; in in vivo screens of erythrocytes or erythrocyte progenitors from an individual to predict the responsiveness of an individual to a disease therapy. | 11-19-2015 |
Patent application number | Description | Published |
20090205062 | Caspase-9 deficient animals and the use thereof - The invention relates to genetically manipulated animals that are deficient in the expression of Casapse-9, a protein involved in programmed cell death. The invention further relates to methods for preventing specific types of cell death associated with Caspase-9 activation. | 08-13-2009 |
20110136892 | Targeting TGF-beta as a Therapy for Alzheimer's Disease - The invention includes compositions and methods for enhancing peripheral macrophage Aβ phagocytosis activity. The invention includes inhibiting a component of TGF-β signaling pathway in peripheral macrophages to promote central nervous system infiltration and beneficial cerebral Aβ clearance. Inhibition of TGF-β signaling in peripheral macrophages represents an advantageous anti-amyloid therapeutic approach for Alzheimer's disease. | 06-09-2011 |
20120240247 | JNK3 MODULATORS AND METHODS OF USE - The c-Jun NH | 09-20-2012 |
20130340105 | Human SIRPAalpha Transgenic Animals and Their Methods of Use - The invention relates generally to compositions and methods of using transgenic non-human animals expressing human SIRPα that are engrafted with a human hematopoietic system. In various embodiments, the human hematopoietic system engrafted, human SIRPα transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, for the in vivo assessment of an immune response, for the in vivo evaluation of vaccines and vaccination regimens, for in vivo production and collection of immune mediators, including human antibodies, and for use in testing the effect of agents that modulate hematopoietic and immune cell function. | 12-19-2013 |
20140377278 | Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders - The present invention relates to the discovery that the disruption of inflammasome function leads to an altered microbiota that affects the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and determining the relative proportions of the constituents of a subject's microbiota, methods of modifying an altered microbiota population in a subject, and compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof. | 12-25-2014 |
20150064265 | Vehicles for Controlled Delivery of Different Pharmaceutical Agents - A “nanolipogel” is a delivery vehicle including one or more lipid layer surrounding a hydrogel core, which may include an absorbent such as a cyclodextrin or ion-exchange resin. Nanolipogels can be constructed so as to incorporate a variety of different chemical entities that can subsequently be released in a controlled fashion. These different incorporated chemical entities can differ dramatically with respect to size and composition. Nanolipogels have been constructed to contain co-encapsulated proteins as well as small hydrophobic drugs within the interior of the lipid bilayer. Agents incorporated within nanolipogels can be released into the milieu in a controlled fashion, for example, nanolipogels provide a means of achieving simultaneous sustained release of agents that differ widely in chemical composition and molecular weight. Additionally, nanolipogels can favorably modulate biodistribution. | 03-05-2015 |
20150132272 | COMPOSITIONS AND METHODS FOR DIMINISHING AN IMMUNE RESPONSE - The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purity and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders. | 05-14-2015 |
Patent application number | Description | Published |
20150020239 | SEED-ORIGIN ENDOPHYTE POPULATIONS, COMPOSITIONS, AND METHODS OF USE - This application relates to methods and materials for providing a benefit to a seed or seedling of an agricultural plant (e.g., an agricultural grass plant), or the agricultural plant derived from the seed or seedling. For example, this application provides purified bacterial populations that include novel seed-origin bacterial endophytes, and synthetic combinations of seeds and/or seedlings (e.g., cereal seeds and/or seedlings) with heterologous seed-derived bacterial endophytes. | 01-15-2015 |
20150320050 | Seed-Origin Endophyte Populations, Compositions, and Methods of Use - This application relates to methods and materials for providing a benefit to a seed or seedling of an agricultural plant (e.g., an agricultural grass plant), or the agricultural plant derived from the seed or seedling. For example, this application provides purified bacterial populations that include novel seed-origin bacterial endophytes, and synthetic combinations of seeds and/or seedlings (e.g., cereal seeds and/or seedlings) with heterologous seed-derived bacterial endophytes. | 11-12-2015 |
20150342196 | Seed-Origin Endophyte Populations, Compositions, and Methods of Use - This application relates to methods and materials for providing a benefit to a seed or seedling of an agricultural plant (e.g., an agricultural grass plant), or the agricultural plant derived from the seed or seedling. For example, this application provides purified bacterial populations that include novel seed-origin bacterial endophytes, and synthetic combinations of seeds and/or seedlings (e.g., cereal seeds and/or seedlings) with heterologous seed-derived bacterial endophytes. | 12-03-2015 |